21 results about "Mouse Spleen" patented technology

This invention discloses an antibody that specifically recognizes Toxoplasma gondii surface antigens and its applications. The invention utilizes hybridoma technology to establish a hybridoma cell line by fusing Balb / C mouse spleen cells with SP2 / 0 cells. Monoclonal antibodies were prepared from these cells using in vitro culture and in vivo ascites induction methods, yielding the monoclonal antibody SH12-S7. This invention provides clinical and research institutions with an antibody that specifically recognizes Toxoplasma gondii surface antigens. It can be used for ELISA assays to detect clinical samples, for immunohistochemical assays to diagnose pathological specimens, and provides a convenient research tool for toxoplasmosis research departments. It has broad application value in the diagnosis and detection of definitive host infections and provides technical support for epidemiological investigations and evaluation of control effects of Toxoplasma gondii.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The application provides application of psoralen in activating NK cells. The psoralen provided by the application is a coumarin component extracted from traditional Chinese medicine psoralea; through in-vitro cell experiment verification, the psoralen can activate NK-92 to secrete IFN-gamma, Granzyme B and Perforion, and activate surface protein NKG2D of NK-92; meanwhile, the psoralen also has the same effect on a cell group containing NK cells; through in-vivo experiment verification, the psoralen helps to improve the total amount of NK cells in the mouse spleen, inhibit tumor growth, and improve the expression amount of IFN-gamma, Granzyme B, Perforion, NKG2D, NKP46 and CD107a in a tumor infiltration environment. In summary, the small-molecule compound psoralen has good effect in activating NK cells.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The present application belongs to the field of biomedical technology, and more particularly relates to the application of Periplaneta americana polypeptide HFDT1 as an immune adjuvant in the preparation of a brucellosis vaccine. The present application uses Brucella OMP10, BP26 and L7 / L12 proteins in combination with HFDT1 to induce mice to produce higher titers of anti-OMP10, BP26 and L7 / L12 protein specific IgG antibodies, and the titers increase with the increase in the number of immunizations, while promoting the body to produce mixed Th1 / Th2 type cellular immune responses and stimulating the proliferation and differentiation of mouse spleen T and B cells, and also facilitating mass production. The Periplaneta americana polypeptide HFDT1 described in the present application is obtained by convenient mass synthesis, and can be used as a novel small molecule immune adjuvant to enhance specific immune responses of the body.

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

The invention relates to the technical field of collagen peptides, in particular to a collagen peptide capable of enhancing immunity and a preparation method thereof.The preparation method comprises the steps that squid skin is subjected to enzymolysis under the alkaline condition to obtain enzymatic hydrolysate, pitch-based activated carbon is added into the enzymatic hydrolysate for decoloration and deodorization, and then low-temperature freeze drying is conducted. The collagen peptide disclosed by the invention can effectively improve spleen and thymus indexes of mice, remarkably improve the phagocytic rate and phagocytic index of macrophages, play a role in enhancing immunity, and have wide application prospects in the fields of health foods and medicines.

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and / or thymus weight loss in a mouse are disclosed as well as uses thereof. 20 24 27 84 77 16 D ec 2 02 4 A B S T R A C T 2 0 2 4 2 7 8 4 7 7 1 6 D e c 2 0 2 4

This invention provides a neutralizing monoclonal antibody 3E3 against the hemagglutinin protein of H7 subtype influenza virus and its applications. This antibody specifically recognizes the hemagglutinin protein of H7 subtype influenza virus and exerts an antiviral effect through neutralization. The hybridoma cells that produce this monoclonal antibody are obtained by fusing BALB / C mouse spleen lymphocytes immunized with purified hemagglutinin protein and mouse myeloma cells SP2 / 0 through a process of cloning, selection, and passage, ultimately resulting in cells that stably secrete antibody 3E3. The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID No. 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 4. 3E3 can effectively bind to, neutralize, and treat H7 subtype influenza virus infection.

This invention discloses the application of Huanglian Shangqing tablets combined with glucocorticoids in the preparation of drugs for treating leukemia. The Huanglian Shangqing tablets combined with glucocorticoids can inhibit the activity of Jurkat cells in a concentration-dependent manner; inhibit the proliferation of Jurkat cells in a concentration- and time-dependent manner; and significantly induce apoptosis in the human acute lymphoblastic leukemia cell line Jurkat. In animal experiments, compared with the model group, the Huanglian Shangqing tablets combined with glucocorticoids can increase the hematocrit ratio of leukemia mice, reduce the spleen burden in mice, have no obvious toxic side effects, and improve the survival rate of leukemia mice. Therefore, the Huanglian Shangqing tablets combined with glucocorticoids have the potential value of developing drugs to reverse glucocorticoid resistance in leukemia. Furthermore, Huanglian Shangqing tablets are already used clinically, which can effectively shorten the preclinical research period and has a very good application prospect.

The present application relates to the technical field of biological medicine, and particularly relates to an anti-Aβ 42 Monoclonal antibody, preparation method and application. The present application adopts Aβ 42 protein of human origin as an immunogen to immunize BALB / c mice, extracts B lymphocytes of the spleen of the mice after successful immunization, fuses the B lymphocytes with mouse myeloma cells SP2 / 0 through cell fusion technology, and obtains hybridoma cell strains stably secreting anti-Aβ 42 monoclonal antibody after three rounds of subclone screening, so as to obtain anti-Aβ 42 monoclonal antibody; the anti-Aβ 42 monoclonal antibody can specifically combine with Aβ 42 protein, and can be used for immunological detection, has a broad market prospect, and can have important clinical significance for further development of biological monitoring technology and therapeutic drugs taking Aβ 42 as a target.

The application discloses a Rhododendron molle flower extract with immunosuppressive activity and a preparation method and application thereof. The Rhododendron molle flower extract is prepared by taking dried flower powder of Rhododendron molle as raw material and 95% ethanol as an extracting agent under the following conditions: condensation reflux extraction for 2 hours at 60 DEG C and a material-liquid ratio of 1:10. The extract is filtered and collected, and the above extract is combined and concentrated under vacuum and reduced pressure to obtain the Rhododendron molle flower extract. The extract has an inhibitory rate of 61.41% on T lymphocyte proliferation induced by abrin and an inhibitory rate of 51.54% on B lymphocyte proliferation induced by lipopolysaccharide at a concentration of 100 mg / mL, and has no cytotoxicity on normal mouse spleen lymphocytes. The application provides a candidate research material for researching and developing a new immunosuppressant, and provides a scientific basis for developing and utilizing the Rhododendron molle resources.

The invention discloses an epitope peptide of avian leukosis virus J subgroup envelope protein GP85, a hybridoma cell strain 3G10E12C4, a monoclonal antibody (mAb) generated by the hybridoma cell strain 3G10E12C4 and application of the monoclonal antibody (mAb). An ALV-J subgroup GP85 protein FE10 epitope peptide is expressed on the surface of an engineering bacterium DH5alpha through a MisL protein passenger-carrying structural domain of a salmonella V-type secretion system in an exhibiting manner and serves as an immunogen to immunize a BALB / c mouse, meanwhile, the FE10 epitope peptide is inserted into a peg pilus operon, an inert carrier bacterium S9H is introduced, the FE10 epitope peptide serves as a detection system, mouse splenocytes and SP2 / 0 cells are fused, and a detection result is obtained. And the monoclonal antibody is obtained through double screening of ELISA (enzyme-linked immuno sorbent assay) and detection targets. The mAb prepared from the hybridoma cell can be specifically combined with the ALV-J strain infected with the HD-11 cell, and has potential application value and prospect in detection, treatment and purification of the ALV.

The invention discloses an application of a diarrhea stopping capsule in preparation of a medicine for treating leukemia, the diarrhea stopping capsule can inhibit proliferation of leukemia cells HEL, KG-1a, K562 and Jurkat, and the inhibition effect on the cells HEL is dose-dependent and time-dependent; the drug-containing serum of the Xiaoshui capsule blocks the cell cycle of human erythroleukemia cells HEL in the G1 phase, and can obviously induce apoptosis of the human erythroleukemia cells HEL. Furthermore, in-vivo experiments show that low, medium and high dosages of the Xiaoshui capsules have no influence on liver and kidney functions of mice; the diarrhea stopping capsule can reduce the weight of the spleen of a mouse with leukemia, increase the hemolysis-to-solution ratio, improve the spleen structure, reduce the expression of a CD71 + cell population, promote differentiation of the spleen and immature red blood cells of bone marrow to a Ter119 + cell population and recover the spleen structure of the mouse. The Xiaoshui capsule is a clinical Miao medicine, can effectively shorten the preclinical research, and has a good application prospect in preparation of medicines for treating myelogenous and lymphatic leukemia.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

The invention provides an anti-human PD-1 monoclonal antibody with agonistic activity or an antigen binding fragment thereof and application of the anti-human PD-1 monoclonal antibody. The anti-human PD-1 monoclonal antibody with agonistic activity or the antigen binding fragment thereof is characterized in that a mouse is immunized through in-vitro recombinant expression of protein antigens of human PD-1 Fc and his tags, spleen, bone marrow and lymph node cells of the mouse are collected, and plasma cells of a secreting target cell binding antibody are enriched by adopting a microfluidic droplet sorting system; carrying out single-cell library construction on plasma cells, and carrying out NGS sequencing to obtain antibody sequences naturally paired with light and heavy chains; the method comprises the following steps: selecting an antibody sequence to carry out mammalian cell high-throughput expression, carrying out ELISA detection, flow detection and reporter gene cell line verification, selecting a representative antibody to carry out animal in-vivo experiment verification, and carrying out screening verification to obtain a series of anti-human PD-1 monoclonal antibodies with agonistic activity or antigen binding fragments thereof. The polypeptide has high affinity and high specificity, and has good antigen-antibody binding activity and agonistic activity on the cellular level.

This invention provides vaccine adjuvant lipid compounds based on Toll-like receptor agonists and their uses. [Solution] Specifically, the present invention discloses a compound represented by formula (I), its stereoisomer, its N-oxide compound, its solvate, or a pharmaceutically acceptable salt thereof. The mRNA-TLP composition produced with the adjuvant lipid compound of the present invention can significantly improve the targeting of mouse spleen antigen-presenting cells and significantly inhibit tumor growth. TIFF2026109612000078.tif38170

The present invention discloses a Toll-like receptor agonist-based vaccine adjuvant lipid compound and use thereof, and specifically discloses a compound of formula (I), or a stereoisomer, an N-oxide, a solvate, or a pharmaceutically acceptable salt thereof. The mRNA-TLP composition prepared from the adjuvant lipid compound of the present disclosure significantly enhances targeting to antigen-presenting cells in mouse spleen and can significantly inhibit tumor growth.

The application belongs to the technical field of medicine. The monkeypox virus surface membrane antigen H3L protein expressed by Escherichia coli is used as an antigen, and Balb / c mice are inoculated with the H3L protein emulsified with Freund's complete adjuvant, and the antigen is co-immunized for three times. The mouse spleen cells are fused with myeloma cells SP2 / 0 cells to prepare H3L specific hybridoma cells, and then the hybridoma is cloned and detected to screen the hybridoma cells specific to the H3L antibody. After three rounds of antigen specific screening, a high-affinity poxvirus murine monoclonal antibody is obtained, the amino acid sequence of the heavy chain variable region domain is shown as SEQ ID NO. 1 in the sequence table, and the amino acid sequence of the light chain variable region domain is shown as SEQ ID NO. 3 in the sequence table. The antibody has good binding capacity with the antigen H3L through ELISA detection, and has good protection in the in vitro neutralization experiment. The antibody can not only be applied to the research and treatment of diseases caused by poxvirus infection, but also can be used as a tool for poxvirus detection and treatment, and has potential application value in detecting poxvirus infection.

The invention discloses a preparation method of a biological agent for enhancing immune response of an infant hepatitis B vaccine generated by an HBsAg positive mother based on a dendritic cell exosome. The preparation method comprises the following steps: obtaining the dendritic cell exosome; preparing a Dex + HepB biological preparation; establishing an HBV intrauterine exposure animal model; and the Dex + HepB biological agent is used for intervening in HBV intrauterine exposed animals. In application verification, an HBV intrauterine exposure mouse model is constructed to simulate the immune state of an infant born by an HBsAg positive mother. And then, according to an immune procedure of 0-2-4 weeks, injecting the prepared Dex + HepB biological agent into the body of a model mouse. Experimental results show that the preparation can effectively improve the proportion of CD4T cells in the spleen of a mouse, improve the expression level of Th2 type cytokines and remarkably enhance the generation of anti-HBs, so that the immune response of the mouse to hepatitis B vaccines is comprehensively improved.

The invention provides application of FSP1 as a prognostic marker or a therapeutic target of non-early precursor T acute lymphocytic leukemia (non-ETP ALL), and belongs to the technical field of biological medicine. The invention discovers that the high expression of the coding gene AIFM2 of the FSP1 protein prompts that the non-ETP ALL patient is poor in prognosis. The FSP1 is used as a therapeutic target, and the FSP1 inhibitor not only can remarkably kill non-ETP ALL cells, but also can synergistically increase the sensitivity of the non-ETP ALL cells to small-dose cytarabine (Ara-C). In addition, the FSP1 inhibitor is combined with a small dose of Ara-C, so that the infiltration proportion of non-ETP ALL cells in the spleen and bone marrow of the mouse can be obviously reduced. The AIFM2 gene and the FSP1 protein coded by the AIFM2 gene are expected to become a prognostic marker and a therapeutic target of non-ETP ALL.